Clinical Trial

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This research study is studying a targeted therapy as a possible treatment for thyroid cancer. A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. \- The name of the study intervention involved in this study is regorafenib.
Protocol Amendment History 5 changes
critical Trial completed 2026-08-13
critical Primary endpoint(s) modified 2026-08-13
notable Enrollment increased: 8 -> 17 participants 2026-08-13
notable Primary completion moved earlier: 2025-12 -> 2023-08-07 2026-08-13
minor Completion moved earlier: 2025-12 -> 2023-08-07 2026-08-13
Trial Details
NCT Number NCT02657551
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Bayer
Conditions Thyroid Cancer
Enrollment 17 participants
Start Date 2016-01
Primary Completion 2023-08-07 (estimated)
Study Completion 2023-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-12